Member Info for ontarget

Do also look at GPM, which is a UK-listed investment company but invested in over 50 mainly TSX and ASX juniors. So very diversified indeed within the sector.

Btw I picked up 1M of these (MTL) yesterday. Expecting great things over the rest of the year.

Re: "His removal would be the catalyst to a rerate"

This is a fundamental misunderstanding about this company. The whole premise of RRR is based on Bell and his 'special abilities' that you have outlined. Without Bell RRR ends.

Well that's me out unfortunately - not going to hold a stock where key directors see fit to sell large amounts of shares, particularly one that was previously a buyer.

Https://tradingeconomics.com/united-kingdom/construction-pmi

How ironic that all the posters desert when after 6 years it is finally there at the most exciting point for a small pharma, about to start clinical trials!

21 Jul '24 - 17:51 - 25692 of 25692

1.000 5 0

I missed this - but a huge positive for ANGLE?

• Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

https://www.annalsofoncology.org/article/S0923-7534(24)00111-X/fulltext#tbl3

-

Some notes I picked up on (simple enough to understand if your attention span allows):

• In this UPDATED REPORT, the consensus within the group has led to an expansion of the RECOMMENDATIONS to encompass patients with ADVANCED BREAST CANCER and rare tumours such as gastrointestinal stromal tumours, sarcoma, thyroid cancer, and cancer of unknown primary.

-

Considering the EVOLVING FIELD of drug development and genomic data, the European Society for Medical Oncology (ESMO) Precision Medicine Working Group (PMWG) sought to update recommendations for the USE OF NEXT-GENERATION SEQUENCING (NGS) for patients with metastatic cancers published in 2020.

-

Precision Medicine Working Group (PMWG) CONCENTRATED ITS EFFORTS on genomic alterations classified as ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) LEVEL I, since they are the KEY DETERMINANTS for recommending the use of NGS FOR ROUTINE PRACTICE within specific cancer types. IN ADDITION, it was UNANIMOUSLY AGREED to report ESCAT LEVEL II genomic alterations to FACILITATE PATIENT ENROLMENT IN CLINICAL TRIALS and PROMOTE DRUG DEVELOPMENT.

https://www.esmo.org/content/download/535994/10608635/1/ESMO-ESCAT-Framework.pdf

-

ESMO ‘RECOMMENDS’ that CLINICAL RESEARCH CENTRES ‘CARRY OUT’ multigene sequencing for patients with metastatic cancers in order to ACCELERATE CLINICAL RESEARCH.

-

Advanced Breast Cancer (ABC) - Summary of recommendations:

• Considering that tumour NGS CAN SUBSTITUTE germline BRCA1/2 testing in most of the patients, along with the reclassification of ESR1 mutations to level IA, ‘IT IS RECOMMENDED TO CARRY OUT TUMOUR (or PLASMA) SAMPLE’ from a patient with hormone receptor-positive/HER2-negative ABC as ‘STANDARD OF CARE’. The NGS testing should be done after resistance to endocrine therapy to optimise the likelihood of detecting ESR1 mutations. Patients with high likelihood of harbouring germline BRCA1/2 mutations should undergo clinical genetic testing even if these alterations were not detected by tumour NGS.

-

Important Considerations when Ordering an NGS + Technologies to detect fusion genes:

• Chromosomal rearrangements can create potent oncogenic FUSION GENES, which represent IMPORTANT therapeutic TARGETS for precision oncology. Examples of gene fusions for which targeted drugs have been approved are those involving ALK, ROS1, RET, FGFR1/2/3, and NTRK1/2/3. In clinical practice, different technologies are employed for the identification of fusion genes. The advantages and limitations of these techniques are described in the following paragraphs. The MAIN POINT is also to stress the fact that

I disagree on the lifestyle bit - yes the shareprice performance has been dire, and yes, the BOD are paid well considering their performance, BUT a lifestyle company is defined by the motivations of the directors - it's one where the directors are there purely to enrich themselves and don't give a two hoots about developing the company towards shareholder value. RRR is probably the most obvious lifestyle company I am familiar with.

However one only has to watch the webinars here, particular the recent 'R&D day' one to realise the directors here are actually trying to progress the company, despite external appearances. So far they are failing quite miserably to do that, but they are trying. And one day could even succeed.

So yes while it shares some characteristics with a typical AIM lifestyle outfit, IMO it is not correct to call it one.

I can't remember who said it, but to paraphrase a famous investor:

"The big money is not made in the buying or selling, it's in the waiting"

Charlemont Capital added again - now holding 80M shares.

Just like your posts.

Https://expose-news.com/2024/06/12/fda-is-a-front-organisation-there-are-no-technicians-in-the-buildings-no-equipment-and-no-sample-testing-occurs/

Well someone's keen - William Black / Armstrong Investments added c.5m shares yesterday. Now holding 5.9%.

Agree rebarm, a competant board on display there. They are clearly not the typical AIM lifestyle suits some would like to make them out to be. They have however had a run of bad luck - first the COVID trial result (which in hindsight was always doomed to failure, big pharma wanted everone to get their 'vaccines' so no interest in actual treatments), then Juvenescence changng strategy and now Stalicla seemingly dragging their heels on the milestone payment.

On the other hand this is clearly priced in at a £2m market cap!

And so well worth a gamble on the Stalicla situation being resolved at some point this year.

"Imagine a small AIM company spending millions developing a capsule without knowing what it does lol "

Umm.. how exactly would you expect any pharma to conduct clinical trials without first developing the prospective drug? Bit of a catch-22?

Just tried it on the IG mobile app (you can get sell quotes for stock you don't hold):

Sell £10k is 0.0368p

Sell £15k is (gulp) 0.0309p

For a decent move now. Just need that RNS to kick it off.

All 5 MMs now on the 0.10 bid. Looking good for further rises.

You might want to take a look at GPM Sinterklaase if you want something that is invested in 40-50 mainly ASX and TSX-listed producers, developers etc. and historically has outperformed GDXJ etc. in gold bull runs.

When is the AGM?

Level 2 looks the best I've seen it here - 3 MMs on the bid, just 1 left on the 7p offer. Should move up soon.